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Abstract The mSim-1 and mSim-2 gene products are mamma-
lian homologues of the Drosophila Sim gene. The dSim gene
product transactivates through a DNA binding site known as the
CNS midline enhancer (CME) element. We have investigated the
transcriptional properties of mSIM-1 and mSIM-2 mediated
through the CME element in concert with their dimerization
partners, ARNT and ARNT-2. The mSIM-1/ARNT heterodimer
transactivates reporter constructs via the ARNT carboxy-
terminus. However, mSIM-2 quenches ARNT transactivation.
We find that mSIM-2 competes with mSIM-1 for binding to
ARNT, suggesting a possible antagonism between these tran-
scription factors.
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1. Introduction
The basic helix-loop-helix PAS [Per-Arnt-Sim] (bHLH-
PAS) proteins contain a bHLH dimerization and DNA bind-
ing motif [1] as well as a second dimerization domain known
as the PAS domain. The PAS domain is designated as a con-
served region among the ¢rst three proteins (PER, ARNT and
SIM) found to contain amino acid similarity over 250^300
amino acids including two degenerate hydrophobic repeats
of approximately 50 amino acids termed PAS A and PAS
B. These individual repeats exhibit homology to a much
broader family of PAS containing proteins involved in a
wide variety of physiological and functional roles [2].
Members of the bHLH-PAS protein family include both
subunits of the dioxin receptor complex, AHR (aryl hydro-
carbon receptor) and ARNT (aryl hydrocarbon receptor nu-
clear translocator) [3], the hypoxia-inducible factors, HIF-1K
and EPAS1/HIF-2K [4,5], as well as the Drosophila single-
minded (dSim) gene product which is critical to the develop-
ment of the midline cells of the central nervous system [6].
Several groups have reported on the cloning of mammalian
Sim homologs [7^11]. The Sim-1 gene has been shown to be
critical for the development of neuroendocrine lineages [12]
and the Sim-2 gene maps to the Down syndrome critical re-
gion [13]. Both mammalian Sim homologs are expressed in the
adult kidney and the developing central nervous system in
overlapping regions [8,9]. The Sim-1 gene is also expressed
in the somites where it is an early marker of presomitic me-
soderm and lateral dermatome [9,14]. The Sim-2 gene is
strongly expressed in a number of cartilage primordia, partic-
ularly in a number of craniofacial structures deriving from the
¢rst pharyngeal arch as well as ribs and vertebrae [9,10,15].
The murine mSIM-1 and mSIM-2 proteins form heterodimers
with the ARNT and ARNT-2 proteins [7,8,10,16^18].
dSim upregulates gene expression through binding of the
CNS midline enhancer (CME) element (5
0
G/ATACGTGA3
0
)
[19^21] and has transcriptional activation properties mapping
to its carboxy-terminus [8,22]. In contrast, we and others have
shown, using GAL4 fusion proteins, that both mSIM proteins
have repressive functions in their carboxy-termini [8,17]. How-
ever, the transcriptional properties of these proteins have not
been investigated in their wild type form, with a heterodimer-
ization partner, in the context of a native DNA binding site.
Herein we report that mSIM-1 and mSIM-2, in concert
with either ARNT or ARNT-2, are able to regulate reporter
constructs containing CME sites. Our data suggest that the
mSIM-1/ARNT heterodimer can strongly transactivate tran-
scription via the transactivation domain of ARNT. In con-
trast, mSIM-2/ARNT heterodimers do not transactivate, due
to the repression activity present within the carboxy-terminus
of mSIM-2. We also ¢nd that mSIM-2 can interfere with the
transactivational properties of mSIM-1/ARNT through com-
petition for dimerization with ARNT as well as for DNA
binding site occupation.
2. Materials and methods
2.1. Cell lines, transfections and CAT assays
C33A and 293 cells were maintained in K-modi¢ed Eagle’s medium
supplemented with 10% heat-inactivated fetal calf serum (Gibco
BRL), penicillin, and streptomycin. Cells were transfected by the cal-
cium phosphate precipitation method [23]. To normalize for trans-
fection e⁄ciency, cells were co-transfected with 0.5 Wg of pcDNA3/
L-gal. At 48 h after transfection, cells were harvested and assayed for
L-galactosidase and luciferase activity [23].
2.2. Recombinant plasmids
Subcloning and mutagenesis were carried out according to standard
protocols [23]. All constructs made via PCR were sequenced to ensure
the absence of mutations. To make reporter constructs containing
the toll 4 CME site [20] two tandem repeats of the sequence
50GGAGCATGCAAGCTTAGAT(CTAGAAATTTGTACGTGCC-
ACAGA)3GGATCCGTG3
0
, where the core CME consensus sequence
is underlined, were cloned into the HindIII/BglII sites of pML [24].
Reporter constructs containing mutated versions of the CME element
(pML/6C-X and pML/6CAM) were constructed using the same strat-
egy with mutations in the core CME (Fig. 1).
The expression construct pcDNA3/mSIM-1 was obtained as a gift
from Dr. C.-M. Fan (Carnegie Institute of Washington, Baltimore,
MD). A series of deletion mutants of the mSIM proteins was con-
structed as shown schematically in Fig. 2A as well as series of chi-
meric constructs between mSIM-1 and mSIM-2 as described in Sec-
tion 3.4 (Fig. 3A) were generated using standard PCR mutagenesis
and subcloning procedures [17,23]. Detailed information on plasmid
construction is available from the authors upon written request. Ex-
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pression vectors for ARNT have been previously described [25]. To
make pcDNA3/hHIF-1KvC (aa 1^403), pcDNA3/hHIF-1K [5] was
digested with P£MI and XbaI, followed by repair with T4 polymerase,
and ligation-recircularization with a linker containing an in frame
stop codon (5
0
pCTAGTCTAGACTAG3
0
[New England Biolabs]).
To construct pcDNA3/dSIM the NheI/SalI fragment of pNB40/
dSIM (a gift from Dr. S. Crews, University of North Carolina, Chapel
Hill, NC) was subcloned into the NheI/XhoI sites of pcDNA3. The
construct pcDNA3/ARNT-2 was made by transferring the EcoRI
fragment of pBSK/mARNT-2 [16] into the EcoRI site of pcDNA3.
2.3. Antibodies and Western blots
Whole cell extracts were fractionated by SDS-PAGE and trans-
ferred to Immobilon-P membrane (Millipore). Membranes were pre-
blocked with 6% bovine serum albumin and incubated with indicated
antibodies in TBST. Hemagglutinin (HA) epitope tagged proteins
were visualized with HA.11 (BabCo, Richmond, CA) and mSIM-2
proteins were visualized using Ab 1850, a polyclonal rabbit antiserum
raised against amino acids 359^566 of mSIM-2. Primary antibodies
were detected with a peroxidase-conjugated sheep anti-mouse or don-
key anti-rabbit immunoglobulin (Amersham) and detected by chem-
iluminescence (NEN).
3. Results
3.1. Mammalian SIM proteins can activate through a
CME site
To investigate the transcriptional properties of the mamma-
lian SIM proteins we constructed reporter plasmids contain-
ing multimerized CME sites, as well as mutant derivatives
thereof (Fig. 1A). When a CME containing reporter construct
(pML/6C-WT) was cotransfected into C33A cells with ARNT
and mSIM-1 or mSIM-2, strong transactivation was observed
with mSIM-1 (Fig. 1B, lane 3). However, the activity seen
with mSIM-2 (Fig. 1C, lane 3) was not signi¢cantly greater
than that observed with the negative control reporter, pML/
6C-X (Fig. 1C, lane 6). No activation by mSIM-2 was seen in
other cell lines (CHO, 293 and COS-7) with this, or other,
reporter construct (Figs. 3^5 and P. Mo¡ett, data not shown).
As expected, the positive control, dSIM, was also able to
activate this reporter (Fig. 1D, lane 3). Since the consensus
DNA binding site for HIF-1K (5
0
T/GACGTGCGG3
0
) [4] is
similar to the CME, we also tested a constitutively active
version of HIF-1K (HIF-1KvC) [26] on this reporter con-
struct. This construct is also able to transactivate pML/6C-
WT (Fig. 1E, lane 3) demonstrating that the SIM and HIF-1K
proteins can activate through similar DNA binding sites.
None of the SIM-like proteins could e¡ect a signi¢cant re-
sponse from the pML parent vector lacking CME sites or
from reporters containing mutant derivatives (pML/6C-AM
or pML/6C-X) (Fig. 1B^D, lanes 5^7; Fig. 1E, lanes 4^6).
The mutation in pML/6C-AM disrupts the ARNT binding
half site of the CME and in pML/6C-X, the SIM binding
half site has been mutated to resemble a xenobiotic response
element (XRE) [3].
Activation was also dependent on inclusion of ARNT (Fig.
1B^E, lane 2). Presumably, endogenous ARNT is limiting in
cotransfection experiments, where exogenous proteins are ex-
pressed to high levels and reporters are at high copy number.
This allowed us to investigate the contribution to transactiva-
tion by the ARNT carboxy-terminus [27]. When ARNTvC
was used in place of ARNT, dSIM still transactivated, albeit
to a lesser extent (Fig. 1D, lanes 3 and 4). In contrast, mSIM-
1 and mSIM-2 were unable to activate transcription in concert
with ARNTvC (Fig. 1C,D, lane 4), suggesting that activation
by mSIM-1/ARNT is dependent on the ARNT transactiva-
tion domain. Similar results were also obtained in C33A,
CHO and COS-7 cells with both luciferase and CAT based
reporters (P. Mo¡ett, data not shown), indicating that this is
not a cell type or reporter speci¢c phenomenon.
3.2. Deletion analysis of mammalian SIM proteins.
We undertook structure^function analysis of mSIM-1 and
mSIM-2 in an attempt to determine the contribution of the
carboxy-termini and basic DNA binding domains of the
mSIM proteins (Fig. 2). As a further control to demonstrate
that the transcriptional e¡ects of mSIM-1 and mSIM-2 were
due to DNA binding, we cotransfected mSIM constructs lack-
ing the basic DNA binding domains (aa 1^13) with ARNT
and the pML/6C-WT reporter into 293 cells (Fig. 2A). As
expected, neither mSIM-1 nor mSIM-2 deletion mutant is
able to e¡ect transactivation in combination with ARNT
(Fig. 2B, compare mSIM-1 versus mSIM-1vb and mSIM-2
versus mSIM-2vb). Western blotting showed similar levels
of expression of the full length and vb mutant proteins
(Fig. 2C, lanes 2, 3, 8, and 9).
We investigated whether the carboxy-terminus of ARNT is
su⁄cient for transactivation, and if the carboxy-termini of the
mSIM proteins contribute to transcriptional control. To this
end, 293 cells were cotransfected with pML/6C-WT, ARNT,
and various mSIM expression vectors. In this context, mSIM-
1 e¡ected potent activation of the reporter construct (Fig. 2B,
V46-fold). A similar degree of activation (Fig. 2B, V23-fold)
with mSIM-1vC (aa 1^384) was seen, con¢rming that ARNT
is likely responsible for most of the observed transactivational
properties. The mSIM-2/ARNT complex does not transacti-
vate in this context (Fig. 2B). The di¡erence between mSIM-1
and mSIM-2 is not due to di¡erences in expression levels (Fig.
2C, lanes 5 and 6). However, when the carboxy-terminus of
mSIM-2 is deleted, mSIM-2vC (aa 1^360) can activate to a
level comparable to mSIM-1vC (Fig. 2B, compare mSIM-
2vC and mSIM-1vC), suggesting that mSIM-2 has repressive
activity in its carboxy-terminus, which quenches the transac-
tivation properties of ARNT. Using fusion proteins, we have
previously identi¢ed two independent repression domains in
the mSIM-2 carboxy-terminus [17]. To determine the regions
of the mSIM-2 carboxy-terminus necessary for quenching
ARNT we employed several deletion constructs (Fig. 2A).
Deleting amino acids 504^657 (Fig. 2A, mSIM-2ST-PS) re-
sults in a polypeptide containing a proline/serine (P/S) rich
region (aa 384^503) which has been shown to have a repres-
sive function [17]. However, in this context the P/S region
alone is unable to quench the transactivation of ARNT since
mSIM-2ST-PS is able to e¡ect transactivation to a similar
degree as mSIM-2vC (Fig. 2B). The adjacent proline and
alanine (P/A) rich region has also been demonstrated to re-
press transcription when fused to a heterologous DNA bind-
ing domain [17]. Deletion mutants mSIM-2vS and mSIM-
2v10 (lacking amino acids 609^657 and 648^657 respectively;
Fig. 2A) have properties intermediate to mSIM-2vC and
mSIM-2 (Fig. 2B). Western blotting with an anti-SIM-2 anti-
body did not show signi¢cantly di¡erent levels of mutant
proteins (Fig. 2C, lanes 8^12). These results demonstrate
that the full P/A, if not the entire carboxy-terminal region,
is necessary for the quenching activity of mSIM-2. As well, we
¢nd that the mSIM-1 and mSIM-2 proteins and their deletion
derivatives can form complexes with ARNT-2 with transcrip-
tional activities similar to that obtained with ARNT (Fig. 2B,
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compare ARNT with ARNT-2). Similar results were also ob-
tained in C33A, CHO and COS-7 cells (P. Mo¡ett, data not
shown).
3.3. Activities of mSIM-1 and mSIM-2 chimeras
Having shown di¡erences in the transcriptional output of
mSIM-1/ARNT and mSIM-2/ARNT, we wished to de¢ne the
structural elements required for this phenomenon. To this
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end, we constructed several fusion proteins exchanging vari-
ous domains of the two SIM proteins (Fig. 3A). These con-
structs consisted of three classes: swapping the carboxy-termi-
ni (aa 348 to carboxy-terminus; mSIM-1/1/2 and mSIM-2/1/
1), the PAS domains (aa 89^347; mSIM-1/2/1 and mSIM-2/1/
2), or the bHLH domains (aa 1^88; mSIM-1/2/2 and mSIM-2/
1/1). As well, mSIM-1 and mSIM-2 di¡er in their basic re-
gions by a single amino acid (10R in mSIM-1 and 10K in
mSIM-2), and a construct was made to express mSIM-2
with its DNA binding domain altered to be identical to that
of mSIM-1 (mSIM-2 KCR). These fusion constructs were
cotransfected into 293 cells in conjunction with pML/6C-
WT and an ARNT expression vector. In this set of experi-
ments mSIM-1 transactivated, on average, 16-fold over back-
ground whereas mSIM-2 had little e¡ect. When the carboxy-
termini were swapped, ARNT/mSIM-1/1/2 activity was re-
duced to 67% of wild type mSIM-1 but not reduced to the
level of wild type mSIM-2 (Fig. 3B). Transferring the car-
boxy-terminus of mSIM-1 to mSIM-2 resulted in a fusion
protein (mSIM-2/2/1) with essentially the same activity as
mSIM-1 (Fig. 3B).
To investigate whether the PAS domains of mSIM-1 and
Fig. 2. Delineation of domains necessary for activation. A: Schematic representation of mSIM-1 and mSIM-2 deletion constructs. Solid boxes
denote the PAS repeats and lightly hatched boxes represent extended sequence similarity to the PER, AHR and ARNT proteins. Crosshatched
boxes represent the HLH region and horizontally hatched boxes represent the DNA binding basic region. Gray boxes represent the HA epitope
tag. B: 293 cells were transfected with 2 Wg pML/6C-WT, 4 Wg ARNT or ARNT-2 expression vectors plus 4 Wg pcDNA3 (basal level) or the
indicated SIM construct. The vertical axis represents fold activation above basal level, which was arbitrarily set at one. Each transfection was
repeated at least three times and error bars represent standard error. Solid bars represent transfections performed with ARNT and open bars
represent transfections performed with ARNT-2. C: Western blot analysis of mSIM proteins. 293 cells were transfected with 4 Wg of the appro-
priate expression vector (indicated at the top of each lane). Whole cell extracts were separated on a 9% SDS-PAGE and proteins detected as
described in Section 2 using either an anti-HA epitope or anti-mSIM-2 antibody as indicated below each blot. Molecular weight markers
(NEB) are indicated (in kDa) to the left of the blots. In lane 6, a HA epitope tagged mSIM-2 expression vector (see Fig. 4A) was transfected.
Fig. 1. Activation of transcription by SIM-like proteins. A: Schematic representation of reporter constructs. An open box represents the lucifer-
ase cDNA. The minimal adenovirus major late promoter (334 to +33) is represented by a black box with the start site indicated by a right-
angled arrow. A hatched box with the core CME or mutated derivative sequence indicated above represents a tandem array of six CMEs (or
derivatives). Mutated bases are underlined. B^E: C33A cells were transfected with 2 Wg of reporter construct (indicated below each graph)
along with 4 Wg of the indicated construct expressing SIM (indicated above each graph), pcDNA3 (lane 1), or HIF-1vC, as well as either 4 Wg
of ARNT, ARNTvC, or pcDNA3 (lane 2). Graph bars indicate fold activation over baseline, which was arbitrarily set at one and represents
the luciferase activity of the appropriate reporter vector alone with 8 Wg of pcDNA3. Each transfection was repeated at least three times and
error bars represent standard error.
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mSIM-2 can a¡ect ARNT transactivation properties, we ex-
changed the PAS domains of the two proteins. Placing the
mSIM-2 PAS domain in the context of mSIM-1 (mSIM-1/2/
1) did not signi¢cantly in£uence the activity of mSIM-1 (Fig.
3B). However, placing the mSIM-1 PAS domain in the con-
text of mSIM-2 somewhat relieved the repressive activity of
mSIM-2 such that the resulting fusion protein (mSIM-2/1/2)
activated to a level 50% of wild type mSIM-1 (Fig. 3B).
When the bHLH domain of mSIM-1 was present in the
context of mSIM-2, the resulting fusion protein (mSIM-1/2/
2) acted analogously to wild type mSIM-2. Likewise, the
bHLH domain of mSIM-2 did not a¡ect mSIM-1 activity
(mSIM-2/1/1). As well, mutating the basic domain of
mSIM-2 to resemble that of mSIM-1 did not signi¢cantly
a¡ect the activity of mSIM-2 (mSIM-2KCR) either (Fig.
4B). Western blot analysis using an anti-HA epitope antibody
showed that di¡erences in fusion protein expression are not
responsible for the observed di¡erences in activity (P. Mo¡ett,
data not shown).
3.4. Competition between mSIM proteins
We sought to investigate whether the mSIM proteins could
compete for limiting amounts of ARNT and/or binding site
occupancy. To this end, 293 cells were cotransfected with
pML/6C-WT, ARNT, and varying amounts of SIM proteins.
Transfecting mSIM-1 alone with ARNT resulted in a repro-
ducible 15-fold activation (Fig. 4A, compare lanes 1 and 2).
Cotransfecting mSIM-1 and increasing amounts of mSIM-
2vb, which can bind ARNT but not DNA [17], resulted in
a dose dependent decrease in mSIM-1 mediated activation,
with up to a three-fold reduction of mSIM-1 mediated acti-
vation (Fig. 4A, lanes 3^7). However, transactivation by
mSIM-1/ARNT was reduced to a greater extent even at rela-
tively low amounts of co-transfected mSIM-2 (Fig. 4B, lane
3), and entirely abolished when twice as much mSIM-2 as
mSIM-1 was transfected (Fig. 4B, lane 6).
We also investigated whether mSIM-1 could interfere with
the action of mSIM-2 by cotransfecting constructs expressing
ARNT and mSIM-2vC along with excess amounts of mSIM-
1vb, which can still bind to ARNT, but not DNA [18]. Even
when three-fold excess mSIM-1vb expression vector is co-
transfected with mSIM-2vC there is no decrease in activation
by ARNT/mSIM-2vC (Fig. 4C, compare lanes 3 and 4).
4. Discussion
Binding to a CME site by mSIM-1/ARNT, but not mSIM-
2/ARNT, has been demonstrated in vitro [18] but transcrip-
tional regulation via this site has not been investigated for
either protein. We ¢nd that, like dSIM, both mSIM-1 and
mSIM-2 can interact with CME sites. This interaction is de-
pendent on the presence of ARNT or ARNT-2 (Figs. 1 and
2), the DNA binding domains of the mSIM proteins (Fig. 2),
and is abolished by introducing point mutations in the CME
site (Fig. 1).
Whereas dSIM has transactivating properties [19,20], we
¢nd that the mSIM-1/ARNT complex also transactivates
(Fig. 1B). However, this activity seems to be largely a result
of the presence of the ARNT activation domain (Figs. 1B and
2B). Therefore, it appears that the mSIM-1 carboxy-terminus
has neither activation nor repression activity in this context.
In contrast, mSIM-2/ARNT does not activate transcription
Fig. 3. Transcriptional activity of mSIM-1/mSIM-2 fusion proteins.
A: Schematic representation of mSIM-1/mSIM-2 fusion constructs.
Solid boxes denote the PAS repeats and lightly hatched boxes repre-
sent extended sequence similarity to the PER, AHR and ARNT
proteins. Crosshatched boxes represent the HLH region and hori-
zontally hatched boxes represent the DNA binding basic region.
Gray boxes represent the HA epitope tag. The * represents a point
mutation in the mSIM-2 DNA binding domain (10KC10R). In the
case of fusion proteins of mSIM-1 and mSIM-2, the portion of
each protein originating from either mSIM-1 or mSIM-2 is indi-
cated beneath the schematic diagram of the protein. B: 293 cells
were transfected with 2 Wg pML/6C-WT, 4 Wg ARNT, and 4 Wg
pcDNA3 or the SIM expression construct indicated below the bar
graph. The vertical axis represents fold activation relative to mSIM-
1, which was arbitrarily set at 100%. Each transfection was repeated
at least three times and error bars represent standard error.
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(Figs. 1^3) unless the carboxy-terminus is deleted (Fig. 2B).
We interpret this to mean that the carboxy-terminus of
mSIM-2 has a repressive function, which quenches the activity
of the ARNT transactivation. Deletion analysis showed that
the entire carboxy-terminus of mSIM-2 was necessary for this
repressive e¡ect (Fig. 2B).
The fact that mSIM-2 quenches ARNT activation is con-
sistent with our previous results demonstrating the presence of
repression domains in its carboxy-terminus [17]. However, the
involvement of mSIM-1 in transactivation is in contrast to
previous results [8], as well as our own unpublished data, in
a mammalian two hybrid system showing that full length
mSIM-1 represses activation by a GAL4/ARNT fusion pro-
tein. The reason for the di¡erent transcriptional responses is
unclear at this point. We feel that our results, using full length
proteins on a native DNA binding site, more closely re£ect
the in vivo situation. However, mSIM-1 may have di¡erent
properties depending on the manner by which it is recruited to
a promoter. The resolution of this issue awaits the identi¢ca-
tion of downstream targets. At present, the only candidate for
a target gene of a mSIM protein is the brn-2 gene. Michaud et
al. [12] found that mSim-1 is required to maintain expression
of the brn-2 gene, which has a CME consensus site
(33685
0
TTACGTGG3
0
3361) present in its 5P regulatory re-
gion [28]. However, in transient cotransfection assays with
reporter constructs containing the 5P regulatory region [28]
of the human homolog of brn-2, we have not detected trans-
activation or repression by either mSIM-1 or mSIM-2 in con-
cert with ARNT or ARNT-2 (P. Mo¡ett, data not shown).
The e¡ect of mSim-1 on brn-2 may be indirect or may require
additional factors not present in our experimental system. It is
interesting, however, that our results showing that mSIM-1/
ARNT can transactivate would be consistent with mSIM-1
being required for brn-2 expression, whereas it was previously
assumed to be a transcriptional repressor [8].
We employed a panel of domain swapping fusion proteins
to investigate the structural basis of the di¡erence in function
of mSIM-1 and mSIM-2 (Fig. 3). Exchanging the basic region
or the entire bHLH domain did not alter the properties of the
mSIM proteins ruling out the possibility of di¡erences in
DNA binding properties (Fig. 3B). The carboxy-termini ap-
pear to account for the di¡erence in transcriptional properties
between the two proteins as their deletion results in proteins
with similar activity (Fig. 2B). Transferring the mSIM-1 car-
boxy-terminus had little e¡ect on mSIM-2 (Fig. 3B). How-
ever, the full repressive e¡ect of mSIM-2 was not transferable
to mSIM-1 (Fig. 3B). It is unclear why the mSIM-2 carboxy-
terminus is not fully repressive when contiguous with the
mSIM-1 PAS domain, but is possible that the PAS domain
modi¢es the behavior of the carboxy-terminus of the mSIM
proteins. In support of an extended role for the PAS domains
in transcriptional regulation, Zelzar et al. [29] have shown that
Fig. 4. Competition between mSIM proteins. A^C: 293 cells were
transfected with 1 Wg pML/6C-WT, 2 Wg ARNT expression con-
struct, and the indicated amount of pcDNA3/mSIM-1, pcDNA3/
mSIM-2, pcDNA3/mSIM-2vb or pcDNA3/mSIM-2vC expression
constructs. The total amount of transfected DNA was made equal
by compensating with appropriate amounts of pcDNA3. Numbers
on the vertical axis represent fold activation above basal activity ob-
tained with no SIM proteins or derivatives (lane 1) which is set at
one. All transfections were performed at least three times and error
bars indicate standard error.
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the PAS domains of TRH and SIM determine target gene
activation.
Several studies have indicated that competition for a com-
mon dimerization partner may contribute to gene regulation
by bHLH-PAS proteins. For example, the AHR and HIF-1
signalling pathways have been shown to interfere with each
other by competing for limiting amounts of ARNT [30^32].
On the other hand, Mimura et al. [33] showed that, as well as
competing for ARNT binding, AHRR inhibits AHR more
e⁄ciently by competing for DNA binding, and repression of
mutual target genes. Also, Gradin et al. [34] have shown that
a factor that binds the XRE in concert with ARNT inhibits
AHR, but not HIF-1K, signalling demonstrating that ARNT
availability is not rate limiting. These studies imply that tran-
scriptional antagonism between bHLH-PAS transcription fac-
tors may be as important as competition for a common dimer-
ization partner.
Our interpretation of results presented in Section 3.4 is that
excess mSIM-2vb or mSIM-2 is able to sequester ARNT from
mSIM-1 and thus inhibit mSIM-1/ARNT mediated transacti-
vation. The fact that the DNA binding competent form of
mSIM-2 is more e¡ective at inhibiting mSIM-1 mediated
transactivation suggests that the two proteins compete for
DNA binding site occupation as well. When mSIM-1 and
mSIM-2 are present at near equal levels (Fig. 2C, lanes 5
and 6) there is very little activation of a reporter construct
(Fig. 4B, lane 5), implying that mSIM-2 repression is domi-
nant over mSIM-1 mediated activation in this system. As well,
even high levels of mSIM-1vb do not a¡ect mSIM-2vC activ-
ity (Fig. 4C) suggesting that the more important mechanism
may be at the level of antagonistic transcriptional activities on
the same DNA binding site rather than sequestration of
ARNT.
Because ARNT is widely expressed in mammals [35^37] it is
believed that it acts as a general dimerization partner for a
number of bHLH-PAS proteins. Although Arnt2 mRNA has
a more restricted pattern of expression [16,37], the Arnt2 gene
product is very similar in structure and function to ARNT
[16]. We have shown that ARNT and ARNT-2 are equally
capable of transactivating in concert with the mSIM proteins
(Fig. 2B) and are therefore both candidates for the role of in
vivo partner in domains of mutual expression, such as the
diencephalon where both mSim genes [7^12] and Arnt2 are
expressed [16,37].
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